Abstract
From 1996 to November 2004, 131 consecutive patients with relapsed or refractory diffuse large cell lymphoma (DLCL) and Hodgkin's lymphoma (HD) received ESHAP as mobilization chemotherapy before autologous peripheral blood stem cell transplant (ASCT). Patients received fixed dose G-CSF 300 μg SC bid starting 24–36 h after finishing mobilizing ESHAP. In all, four patients failed mobilization and are excluded. Characteristics of 127 patients: 68 males: 59 females. DLCL 49: HD 78. Initial stage I:II:III:IV:unknown was 15:34:33:42:3. Median age at ASCT 26 years. Median prior chemotherapy cycles were six {<6 (17 patients), 6–8 (90 patients), >8 (20 patients)}. Median ESHAP cycle used as mobilizer was third. Patients required 1, 2, 3, 4 apheresis were 93:25:8:1. Median total CD34+ cells/kg collected were 6.9 × 106 (DLCL 5.17 × 106 and HD 7.6 × 106), patients weighing ⩽70 kg (93 patients) 6.54 × 106 and >70 kg (34 patients) 7.44 × 106 (P=0.59), one apheresis (93 patients) 8.6 × 106/kg and >1 apheresis (34 patients) 4.5 × 106 (P=0.001). We conclude that ESHAP and G-CSF 300 μg SC bid is an effective mobilizing regimen even in patients >70 kg and most patients require only 1–2 apheresis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Richman C, Weiner R, Yankee R . Increase in circulating stem cells following chemotherapy. Blood 1977; 47: 1031–1039.
Duhrsen U, Villeval J, Boyd J, Kannourakis G, Morstyn G, Metcalf D . Effects of recombinant Granulocyte Colony Stimulating Factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 10: 2074–2081.
Sheridan W, Begley C, To L, Grigg A, Szer J, Maher D et al. Phase II study of autologous filgastrim (G-CSF) mobilised peripheral blood progenitor cells to restore hemopoiesis after high-dose chemotherapy for lymphoid malignancies. Bone Marrow Transplant 1994; 14: 105–111.
Peters W, Rosner G, Ross M, Vredenburgh J, Meisenberg B, Gilbert C et al. Comparative effects of granulocyte-macrophage colony stimulating factor (GM-CSF) and granulocyte colony stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy. Blood 1993; 81: 1709–1719.
Narayanasami U, Kanteti R, Morelli J, Klekar A, Al-Olama A, Keating C et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98: 2059–2064.
To L, Roberts M, Haylock D, Dayson P, Branford A, Thorp D et al. Comparison of hematologic recovery times and supportive care requirements of autologous recovery phase peripheral blood stem cell transplants, autologous bone marrow transplants and allogeneic bone marrow transplants. Bone Marrow Transplant 1992; 9: 277–284.
Kessinger A, Sharp J . The whys and hows of hematopoietic progenitor and stem cell mobilization. Bone Marrow Transplant 2003; 31: 319–329.
Vellenga E, van Agthoven M, Croockewit A, Verdonck L, Wijermans P, van Oers M et al. Autologous peripheral blood stem cell transplantation in patients with relapsed lymphoma results in accelerated haematopoietic reconstitution, improved quality of life and cost reduction compared with bone marrow transplantation: the Hovon 22 study. Br J Haematol 2001; 114: 319–326.
Glaspy J . Economic consideration in the use of peripheral blood progenitor cells to support high-dose chemotherapy. Bone Marrow Transplant 1999; 23: S21–S27.
Dazzi C, Cariello A, Rosti G, Argnani M, Sebastiani L, Ferrari E et al. Is there any difference in PBPC mobilization between cyclophosphamide plus G-CSF and G-CSF alone in patients with non-Hodgkin's Lymphoma? Leuk Lymphoma 2000; 39: 301–310.
Deliliers G, Annaloro C, Marconi M, Soligo D, Morandi P, Luchesini C et al. Harvesting of autologous blood stem cells after a mobilising regimen with low-dose cyclophosphamide. Leuk Lymphoma 2002; 43: 1957–1960.
Kotasek D, Shepherd K, Sage R, Dale B, Norman J, Charles P et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11–17.
McQuaker I, Haynes A, Stainer C, Anderson S, Russell N . Stem cell mobilization in resistant or relapsed lymphoma. Superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide. Br J Haematol 1997; 98: 228–233.
Morton J, Morton A, Bird R, Hutchins C, Durrant S . Predictors for optimal mobilization and subsequent engraftment of peripheral blood progenitor cells following intermediate dose cyclophosphamide and G-CSF. Leukemia Res 1997; 21: 21–27.
Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P et al. Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant 2002; 29: 285–290.
Shepherd K, Charles P, Sage R, Dale B, Norman J, Kotasek D et al. Mobilization of haemopoietic stem cells by cyclophosphamide into the peripheral blood of patients with haematological malignancies. Clin Lab Haematol 1991; 13: 25–32.
Watts M, Sullivan A, Jamieson E, Pearce R, Fielding A, Devereux S et al. Progenitor-cell mobilization after low-dose cyclophosphamide and granulocyte colony-stimulating factor: an analysis of progenitor-cell quantity and quality and factors predicting for these parameters in 101 pretreated patients with malignant lymphoma. J Clin Oncol 1997; 15: 535–546.
Magagnoli M, Sarina B, Balzarotti M, Castagna L, Timofeeva I, Nozza A et al. Mobilizing potential of ifosfamide/vinorelbine-based chemotherapy in pretreated malignant lymphoma. Bone Marrow Transplant 2001; 28: 923–927.
Petit J, Boque C, Cancelas J, Sarra J, Munoz J, Garcia J et al. Feasibility of ESHAP+G-CSF as peripheral blood hematopoietic progenitor cell mobilisation regimen in resistant and relapsed lymphoma: a single-center study of 22 patients. Leuk Lymphoma 1999; 34: 119–1127.
Watts M, Ings S, Leverett D, MacMillan A, Devereux S, Goldstone A et al. ESHAP and G-CSF is a superior blood stem cell mobilizing regimen compared to cyclophosphamide 1.5 g m(-2) and G-CSF for pre-treated lymphoma patients: a matched pairs analysis of 78 patients. Br J Cancer 2000; 82: 278–282.
Zinzani P, Tani M, Molinari A, Stefoni V, Zuffa E, Alinari L et al. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients. Haematologica 2002; 87: 816–821.
Akhtar S, El Weshi A, Rahal M . ESHAP+fixed dose G-CSF as autologous peripheral blood stem cell mobilisation regimen in patients with relapsed or refractory diffuse large cell and Hodgkin lymphoma: a single institution result of 100 patients. Bone Marrow Transplant 2004; 33: O259.
Velasquez W, McLaughlin P, Tucker S, Hagemeister F, Swan F, Rodriguez M et al. E-SHAP an effective chemotherapy in refractory and relapsing lymphoma: a 4-year follow-up. J Clin Oncol 1994; 6: 1169–1176.
Brocklebank A, Sparrow R . Enumeration of CD34 cells in cord blood: a variation on a single-platform flow cytometric method based on the ISHAGE gating strategy. Cytometry (Comm Clin Cytometry) 2001; 46: 254–261.
Carlo-Stella C, Mangoni L, Piovani G, Garau D, Almici C, Rizzoli V . Identification of Philadelphia-negative granulocyte-macrophage colony-forming units generated by stroma-adherent cells from chronic myelogenous leukemia patients. Blood 1994; 83: 1373–1380.
Andre M, Baudoux E, Bron D, Canon J, D'Hondt V, Fillet G et al. Phase III randomized study comparing 5 or 10 g per kg per day of filgrastim for mobilization of peripheral blood progenitor cells with chemotherapy, followed by intensification and autologous transplantation in patients with nonmyeloid malignancies. Transfusion 2003; 43: 50–57.
Demirer T, Ayli M, Ozcan M, Gunel N, Haznedar R, Dagli M et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002; 116: 468–474.
Weaver C, Birch R, Greco L, Schwartzberg L, McAneny B, Moore M et al. Mobilization and harvesting of peripheral blood stem cells: randomized evaluations of different doses of filgrastim. Br J Haematol 1998; 100: 338–347.
Bensinger W, Appelbaum F, Rowley S, Storb R, Sanders J, Lilleby K et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol 1995; 13: 2547–2555.
Clark R, Brammer C . Previous treatment predicts the efficiency of blood progenitor cell mobilization: validation of a chemotherapy scoring system. Bone Marrow Transplant 1998; 22: 859–863.
Drake M, Ranaghan L, Morris T, Nolan L, Desai Z, Irvine A et al. Analysis of the effect of prior therapy on progenitor cell yield: use of a chemotherapy scoring system. Br J Haematol 1997; 98: 745–749.
Ford C, Chan K, Reilly W, Petersen F . An evaluation of predictive factors for CD34+ cell harvest yields from patients mobilized with chemotherapy and growth factors. Transfusion 2003; 43: 622–625.
Ford C, Green W, Warenski S, Petersen F . Effect of prior chemotherapy on hematopoietic stem cell mobilization. Bone Marrow Transplant 2004; 33: 901–905.
Micallef I, Apostolidis J, Rohatiner A, Wiggins C, Crawley C, Foran J et al. Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J 2000; 1: 367–373.
Lee J-L, Kim S, Kim SW, Kim E-K, Kim S-B, Kang Y-K et al. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF. Bone Marrow Transplant 2005; 35: 449–454.
Acknowledgements
We appreciate the assistance of Aneta Mclean from the apheresis lab and Ibrahim Abdullah Al-Hassan for statistical analysis.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Akhtar, S., Tbakhi, A., Humaidan, H. et al. ESHAP+fixed dose G-CSF as autologous peripheral blood stem cell mobilization regimen in patients with relapsed or refractory diffuse large cell and Hodgkin's lymphoma: a single institution result of 127 patients. Bone Marrow Transplant 37, 277–282 (2006). https://doi.org/10.1038/sj.bmt.1705239
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705239
Keywords
This article is cited by
-
Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant
Annals of Hematology (2018)
-
Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation in adolescent and young adults with relapsed or refractory Hodgkin lymphoma
Annals of Hematology (2016)
-
Autologous peripheral blood stem cell mobilization following dose-adjusted cyclophosphamide, doxorubicin, vincristine, and prednisolone chemotherapy alone or in combination with rituximab in treating high-risk non-Hodgkin’s lymphoma
Chinese Journal of Cancer (2015)
-
Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin’s lymphoma: outcome after high-dose chemotherapy and auto-SCT
Bone Marrow Transplantation (2013)
-
Pre-transplant 18F-fluorodeoxyglucose positron emission tomography-based survival model in patients with aggressive lymphoma undergoing high-dose chemotherapy and autologous SCT
Bone Marrow Transplantation (2013)